CA3094313A1 - Camptothecin peptide conjugates - Google Patents
Camptothecin peptide conjugates Download PDFInfo
- Publication number
- CA3094313A1 CA3094313A1 CA3094313A CA3094313A CA3094313A1 CA 3094313 A1 CA3094313 A1 CA 3094313A1 CA 3094313 A CA3094313 A CA 3094313A CA 3094313 A CA3094313 A CA 3094313A CA 3094313 A1 CA3094313 A1 CA 3094313A1
- Authority
- CA
- Canada
- Prior art keywords
- gly
- alkyl
- camptothecin
- val
- lys
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Cell Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862653961P | 2018-04-06 | 2018-04-06 | |
| US62/653,961 | 2018-04-06 | ||
| PCT/US2019/025968 WO2019195665A1 (en) | 2018-04-06 | 2019-04-05 | Camptothecin peptide conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3094313A1 true CA3094313A1 (en) | 2019-10-10 |
Family
ID=68101237
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3094313A Pending CA3094313A1 (en) | 2018-04-06 | 2019-04-05 | Camptothecin peptide conjugates |
Country Status (16)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4431521A4 (en) * | 2021-12-01 | 2026-04-08 | Shanghai Inst Of Biological Products Co Ltd | ANTIBODY-DRUG CONJUGATE AND ITS USE |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3042428A1 (en) | 2016-11-08 | 2018-05-17 | Regeneron Pharmaceuticals, Inc. | Steroids and protein-conjugates thereof |
| KR20250008984A (ko) | 2017-05-18 | 2025-01-16 | 리제너론 파마슈티칼스 인코포레이티드 | 사이클로덱스트린 단백질 약물 접합체 |
| CA3247730A1 (en) | 2017-11-07 | 2025-10-30 | Regeneron Pharmaceuticals, Inc. | Hydrophilic linkers for antibody drug conjugates |
| WO2019217591A1 (en) | 2018-05-09 | 2019-11-14 | Regeneron Pharmaceuticals, Inc. | Anti-msr1 antibodies and methods of use thereof |
| TWI920652B (zh) | 2018-06-07 | 2026-04-01 | 美商思進公司 | 喜樹鹼結合物 |
| CN110590796B (zh) * | 2018-06-12 | 2022-07-15 | 青岛海洋生物医药研究院股份有限公司 | 喜树碱衍生物及其制备方法和应用 |
| RS64961B1 (sr) * | 2019-04-26 | 2024-01-31 | Immunogen Inc | Derivati kamptotecina |
| CN112125915A (zh) * | 2019-09-18 | 2020-12-25 | 四川百利药业有限责任公司 | 一种喜树碱衍生物及其偶联物 |
| JP7880815B2 (ja) * | 2019-10-01 | 2026-06-26 | メモリアル スローン-ケタリング キャンサー センター | Idタンパク質の小分子阻害剤 |
| WO2021067820A1 (en) * | 2019-10-04 | 2021-04-08 | Seagen Inc. | Formulation of antibody-drug conjugate |
| KR20220079606A (ko) * | 2019-10-04 | 2022-06-13 | 씨젠 인크. | 캄프토테신 펩티드 접합체 |
| BR112022005114A2 (pt) * | 2019-10-04 | 2022-06-21 | Seagen Inc | Anticorpo, composição farmacêutica, métodos para tratar câncer e para produzir um conjugado anticorpo-fármaco e um anticorpo, ácido nucleico, vetor, célula hospedeira, e, conjugado anticorpo-fármaco |
| WO2021143741A1 (zh) * | 2020-01-15 | 2021-07-22 | 北京海步医药科技有限公司 | 靶向多肽-药物缀合物及其用途 |
| CN113274507B (zh) * | 2020-02-20 | 2025-02-28 | 亚飞(上海)生物医药科技有限公司 | 靶向递送和激活的免疫刺激性偶联复合物的制备和用途 |
| US12029736B2 (en) | 2020-02-25 | 2024-07-09 | Mediboston Limited | Camptothecin derivatives and conjugates thereof |
| KR20230023650A (ko) * | 2020-05-13 | 2023-02-17 | 씨젠 인크. | 항-cd30 항체-약물 컨쥬게이트의 조합을 사용하여 암을 치료하는 방법 |
| WO2022078279A1 (zh) * | 2020-10-12 | 2022-04-21 | 昆山新蕴达生物科技有限公司 | 抗体-药物偶联物及其应用 |
| ES2963150T3 (es) | 2020-10-27 | 2024-03-25 | Elucida Oncology Inc | Procedimientos para funcionalizar nanopartículas |
| KR20230133312A (ko) * | 2021-01-15 | 2023-09-19 | 알.피.쉐러 테크놀러지즈 엘엘씨 | 캄프토테신 항체-약물 접합체 및 이의 사용 방법 |
| CN116847844A (zh) * | 2021-01-15 | 2023-10-03 | R.P.谢勒技术有限责任公司 | 喜树碱抗体-药物缀合物及其使用方法 |
| AU2022216696A1 (en) * | 2021-02-05 | 2023-08-17 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Camptothecin compound, preparation method therefor, and application thereof |
| CN120093941A (zh) * | 2021-02-09 | 2025-06-06 | 苏州宜联生物医药有限公司 | 生物活性物偶联物及其制备方法和用途 |
| US12521444B2 (en) * | 2021-02-25 | 2026-01-13 | Fortvita Biologics Limited | Anti-HER2 antibody-drug conjugates and uses thereof |
| WO2022194257A1 (zh) * | 2021-03-17 | 2022-09-22 | 江苏恒瑞医药股份有限公司 | 一种喜树碱衍生物的制备方法 |
| JP2024510435A (ja) | 2021-03-18 | 2024-03-07 | シージェン インコーポレイテッド | 生体活性化合物の内部移行複合体からの選択的薬物放出 |
| CN115109118A (zh) * | 2021-03-19 | 2022-09-27 | 博瑞生物医药(苏州)股份有限公司 | 一种固相合成ds-8201中间体的方法及ds-8201的制备方法 |
| AR125473A1 (es) * | 2021-04-29 | 2023-07-19 | Abbvie Inc | Conjugados de anticuerpo anti-c-met y fármaco |
| EP4349371A4 (en) * | 2021-06-02 | 2025-06-25 | Bio-Thera Solutions, Ltd. | DRUG CONJUGATE AND USE THEREOF |
| CN113527418B (zh) * | 2021-07-16 | 2022-05-03 | 成都普康唯新生物科技有限公司 | 一种ADC linker的制备方法 |
| CA3224492A1 (en) | 2021-07-19 | 2023-01-26 | Xiaojun Han | Immunoconjugates and methods |
| US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
| JP2024532768A (ja) * | 2021-08-19 | 2024-09-10 | ハイナン シムセレ ザイミン ファーマシューティカル カンパニー リミテッド | カンプトテシン誘導体、その薬物組成物およびその応用 |
| CA3233254A1 (en) | 2021-09-27 | 2023-03-30 | Evopoint Biosciences Co., Ltd. | Antibody, antibody-drug conjugate thereof and use thereof |
| PE20242114A1 (es) * | 2021-11-09 | 2024-10-28 | Tubulis Gmbh | Conjugados que comprenden fosforo (v) y una fraccion molecular de camptotecina |
| CN116354976B (zh) * | 2021-12-27 | 2025-01-24 | 上海复旦张江生物医药股份有限公司 | 喜树碱衍生物的纯化方法 |
| KR20240137076A (ko) | 2022-01-25 | 2024-09-19 | 메디링크 테라퓨틱스 (쑤저우) 컴퍼니, 리미티드 | Her3에 대한 항체, 접합체 및 이의 용도 |
| WO2023143208A1 (zh) * | 2022-01-26 | 2023-08-03 | 苏州宜联生物医药有限公司 | 一种药物连接体偶联物的制备方法 |
| KR20240150773A (ko) | 2022-02-24 | 2024-10-16 | 에보포인트 바이오사이언시스 컴퍼니 리미티드 | 항체 및 약물 접합체 및 이의 용도 |
| KR20250004952A (ko) | 2022-03-17 | 2025-01-08 | 씨젠 인크. | 캄프토테신 접합체 |
| KR20240162575A (ko) | 2022-03-25 | 2024-11-15 | 자임워크스 비씨 인코포레이티드 | 엽산 수용체 알파를 표적화하는 항체-약물 접합체 및 사용 방법 |
| AU2023252914A1 (en) * | 2022-04-13 | 2024-10-17 | Arcus Biosciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| CN119255824A (zh) * | 2022-04-14 | 2025-01-03 | 德比欧药物研究有限公司 | 具有改善的药代动力学和药物释放特性的配体-药物缀合物 |
| KR20230149752A (ko) * | 2022-04-20 | 2023-10-27 | 주식회사 피노바이오 | Ddx5 단백질에 결합하는 캄토테신 유도체 및 이의 프로드럭 |
| CN116966314A (zh) | 2022-04-29 | 2023-10-31 | 成都百利多特生物药业有限责任公司 | 一种包含亲水性糖结构的配体-药物偶联物 |
| WO2023214849A1 (ko) * | 2022-05-04 | 2023-11-09 | 주식회사 피노바이오 | Ddx5 단백질에 결합하는 캄토테신계 약물이 산 민감성 링커에 연결된 접합체 및 이를 이용한 면역접합체 |
| US20230357763A1 (en) * | 2022-05-06 | 2023-11-09 | James E. Summerton | Morpholinos with Increased Delivery Efficiency |
| WO2023217227A1 (zh) | 2022-05-12 | 2023-11-16 | 先声再明医药有限公司 | 喜树碱类衍生物及配体-药物偶联物 |
| JP2025515988A (ja) * | 2022-05-13 | 2025-05-23 | シチュアン ケルン-バイオテック バイオファーマシューティカル カンパニー リミテッド | カンプトテシン化合物、その調製方法及びその使用 |
| AU2023278370A1 (en) * | 2022-05-30 | 2025-01-09 | Medilink Therapeutics (Suzhou) Co., Ltd. | Preparation method for drug linker conjugate and intermediate thereof |
| CN118955614B (zh) * | 2022-07-05 | 2025-12-30 | 上海药明合联生物技术有限公司 | 偶联连接子 |
| KR20250049568A (ko) * | 2022-07-15 | 2025-04-11 | 페온 테라퓨틱스 리미티드 | Cdcp1에 결합하는 항체 약물 접합체 및 이의 용도 |
| KR20240035370A (ko) * | 2022-09-08 | 2024-03-15 | 주식회사 피노바이오 | 신규 캄토테신 유도체 및 이를 포함하는 운반체-약물 접합체 |
| CN117752813A (zh) | 2022-09-26 | 2024-03-26 | 成都百利多特生物药业有限责任公司 | 抗cd33抗体和抗cd33抗体-药物偶联物及其用途 |
| WO2024073610A2 (en) * | 2022-09-28 | 2024-04-04 | Solve Therapeutics, Inc. | Compositions and uses thereof |
| JP2025533758A (ja) | 2022-10-14 | 2025-10-09 | スーチュアン・コールン-バイオテック・バイオファーマシューティカル・カンパニー・リミテッド | 抗体-薬物複合体並びにその調製方法及び使用 |
| EP4605425A1 (en) * | 2022-10-18 | 2025-08-27 | Zymeworks BC Inc. | Antibody-drug conjugates targeting glypican-3 and methods of use |
| WO2024114318A1 (zh) | 2022-11-29 | 2024-06-06 | 四川科伦博泰生物医药股份有限公司 | 药物连接子化合物及其制备方法和用途 |
| WO2024129756A1 (en) | 2022-12-13 | 2024-06-20 | Seagen Inc. | Site-specific engineered cysteine antibody drug conjugates |
| CN116712561A (zh) | 2022-12-29 | 2023-09-08 | 杭州爱科瑞思生物医药有限公司 | 含n-亚甲基酰胺连接子的抗体-药物偶联物 |
| KR20250145079A (ko) * | 2023-02-09 | 2025-10-13 | 비원 메디슨즈 아이 게엠베하 | 자가 안정화 링커 접합체 |
| CN118666946A (zh) * | 2023-03-15 | 2024-09-20 | 上海亲合力生物医药科技股份有限公司 | 连接子及使用其的偶联药物、抗体偶联药物及其应用 |
| WO2024210687A1 (ko) * | 2023-04-06 | 2024-10-10 | 주식회사 피노바이오 | 항암 내성 극복을 위한 신규 캄토테신 유도체 및 이를 포함하는 항체-약물 접합체 |
| CN120858098A (zh) * | 2023-05-04 | 2025-10-28 | 四川科伦博泰生物医药股份有限公司 | 稠环化合物及其制备方法和应用 |
| IL324828A (en) * | 2023-06-05 | 2026-01-01 | Tripartite Therapeutics Inc | Polar ligand-drug conjugate |
| CN122121899A (zh) * | 2023-08-18 | 2026-05-29 | 康诺亚生物医药科技有限公司 | 五环类活性化合物及其偶联物和用途 |
| WO2025048588A1 (ko) * | 2023-08-31 | 2025-03-06 | 주식회사 피노바이오 | 신규 캄토테신 유도체 및 이를 포함하는 항체-약물 접합체 |
| CN121843944A (zh) * | 2023-09-06 | 2026-04-10 | 劲方医药科技(上海)股份有限公司 | 大环化合物及其抗体-药物偶联物 |
| IL327670A (en) | 2023-10-11 | 2026-06-01 | Antikor Biopharma Ltd | Antibodies, conjugates, and uses thereof |
| CN120053678A (zh) * | 2023-11-30 | 2025-05-30 | 上海医药集团股份有限公司 | 一种高喜树碱类抗体偶联药物、其制备方法及应用 |
| CN122374343A (zh) | 2023-11-30 | 2026-07-10 | 江苏康宁杰瑞生物制药有限公司 | 包含pd-l1结合分子与双特异性抗体-药物偶联物的组合物及其用途 |
| CN122396493A (zh) * | 2023-12-14 | 2026-07-14 | 上海盟科药业股份有限公司 | 喜树碱类似物的配体-药物偶联物及其用途 |
| AU2024415931A1 (en) | 2023-12-27 | 2026-07-16 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd. | Multi-specific antibody targeting her3 and trop2 and conjugate thereof |
| WO2025149947A1 (en) | 2024-01-12 | 2025-07-17 | Seagen Inc. | Antibody-drug conjugates |
| US20250295801A1 (en) | 2024-03-21 | 2025-09-25 | Seagen Inc. | Cd25 antibodies, antibody drug conjugates, and uses thereof |
| WO2025221986A1 (en) * | 2024-04-18 | 2025-10-23 | Cedars-Sinai Medical Center | Targeted camptothecin derivatives for cancer treatment |
| WO2025223507A1 (zh) * | 2024-04-25 | 2025-10-30 | 江苏康宁杰瑞生物制药有限公司 | 化合物及其偶联物 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0540099T3 (da) | 1991-10-29 | 1996-06-17 | Glaxo Wellcome Inc | Vandopløselige camptothecinderivater |
| JPH06228141A (ja) * | 1992-01-24 | 1994-08-16 | Takeda Chem Ind Ltd | 縮合複素環誘導体、その塩、その製造法および用途 |
| US5496830A (en) * | 1994-09-14 | 1996-03-05 | Johns Hopkins University | Inhibition of hemoflagellates by camptothecin compounds |
| SG88737A1 (en) * | 1996-10-30 | 2002-05-21 | Tanabe Seiyaku Co | S type 2-substituted hydroxy-2-indolidinylbutyric ester compounds and process for preparation thereof |
| EE200100603A (et) * | 1999-05-14 | 2003-02-17 | Imclone Systems Incorporated | Inimese refraktaarsete kasvajate ravi epidermaalse kasvufaktori retseptori antagonistidega |
| US6629995B1 (en) * | 2000-03-31 | 2003-10-07 | Super Gen, Inc. | Camptothecin conjugates |
| US6825206B1 (en) * | 2000-11-16 | 2004-11-30 | Research Triangle Institute | Camptothecin compounds with a thioether group |
| US8877901B2 (en) | 2002-12-13 | 2014-11-04 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
| US7591994B2 (en) * | 2002-12-13 | 2009-09-22 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
| KR101641345B1 (ko) * | 2007-10-12 | 2016-07-20 | 시애틀 지네틱스, 인크. | 항체-약물 접합체를 이용한 병용 요법 |
| US10195288B2 (en) * | 2012-10-11 | 2019-02-05 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate |
| CN105813653B (zh) | 2013-12-19 | 2020-06-26 | 西雅图基因公司 | 与目标-药物偶联物并用的亚甲基氨基甲酸酯连接物 |
| JP7244987B2 (ja) * | 2016-12-14 | 2023-03-23 | シージェン インコーポレイテッド | 多剤抗体薬物コンジュゲート |
| TWI920652B (zh) * | 2018-06-07 | 2026-04-01 | 美商思進公司 | 喜樹鹼結合物 |
| KR20220079606A (ko) * | 2019-10-04 | 2022-06-13 | 씨젠 인크. | 캄프토테신 펩티드 접합체 |
| BR112022005114A2 (pt) * | 2019-10-04 | 2022-06-21 | Seagen Inc | Anticorpo, composição farmacêutica, métodos para tratar câncer e para produzir um conjugado anticorpo-fármaco e um anticorpo, ácido nucleico, vetor, célula hospedeira, e, conjugado anticorpo-fármaco |
| KR20230023650A (ko) * | 2020-05-13 | 2023-02-17 | 씨젠 인크. | 항-cd30 항체-약물 컨쥬게이트의 조합을 사용하여 암을 치료하는 방법 |
| CA3203777A1 (en) * | 2020-12-03 | 2022-06-09 | Seagen Inc. | Modulating the immune response using anti-cd30 antibody-drug conjugates |
| JP2025501978A (ja) * | 2022-01-05 | 2025-01-24 | アジェンシス,インコーポレイテッド | 191p4d12タンパク質に結合する抗体薬物コンジュゲート(adc)で筋層浸潤性尿路上皮癌または筋層浸潤性膀胱癌を治療するための方法 |
| KR20250004952A (ko) * | 2022-03-17 | 2025-01-08 | 씨젠 인크. | 캄프토테신 접합체 |
-
2019
- 2019-04-05 CN CN201980024331.XA patent/CN111936169A/zh active Pending
- 2019-04-05 JP JP2020554542A patent/JP7430643B2/ja active Active
- 2019-04-05 IL IL310391A patent/IL310391A/en unknown
- 2019-04-05 EP EP19781578.0A patent/EP3773736A4/en not_active Withdrawn
- 2019-04-05 WO PCT/US2019/025968 patent/WO2019195665A1/en not_active Ceased
- 2019-04-05 KR KR1020207031963A patent/KR20210006362A/ko not_active Withdrawn
- 2019-04-05 AR ARP190100908A patent/AR114473A1/es not_active Application Discontinuation
- 2019-04-05 CA CA3094313A patent/CA3094313A1/en active Pending
- 2019-04-05 US US16/376,302 patent/US20190343828A1/en not_active Abandoned
- 2019-04-05 BR BR112020020466-8A patent/BR112020020466A2/pt not_active IP Right Cessation
- 2019-04-05 MX MX2020010458A patent/MX2020010458A/es unknown
- 2019-04-05 MA MA052669A patent/MA52669A/fr unknown
- 2019-04-05 AU AU2019247434A patent/AU2019247434A1/en not_active Abandoned
- 2019-04-05 EA EA202092410A patent/EA202092410A1/ru unknown
- 2019-04-05 IL IL277748A patent/IL277748B2/en unknown
- 2019-04-05 SG SG11202009527PA patent/SG11202009527PA/en unknown
- 2019-04-08 TW TW108112067A patent/TW202010498A/zh unknown
-
2021
- 2021-10-27 US US17/452,516 patent/US20220193069A1/en not_active Abandoned
-
2023
- 2023-10-27 US US18/496,756 patent/US20250135018A1/en not_active Abandoned
-
2024
- 2024-01-31 JP JP2024012728A patent/JP2024042054A/ja active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4431521A4 (en) * | 2021-12-01 | 2026-04-08 | Shanghai Inst Of Biological Products Co Ltd | ANTIBODY-DRUG CONJUGATE AND ITS USE |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019247434A1 (en) | 2020-10-08 |
| CN111936169A (zh) | 2020-11-13 |
| JP2024042054A (ja) | 2024-03-27 |
| EP3773736A1 (en) | 2021-02-17 |
| IL277748A (en) | 2020-11-30 |
| BR112020020466A2 (pt) | 2021-01-12 |
| EP3773736A4 (en) | 2022-01-05 |
| KR20210006362A (ko) | 2021-01-18 |
| SG11202009527PA (en) | 2020-10-29 |
| TW202010498A (zh) | 2020-03-16 |
| US20250135018A1 (en) | 2025-05-01 |
| US20190343828A1 (en) | 2019-11-14 |
| IL277748B1 (en) | 2024-03-01 |
| MX2020010458A (es) | 2021-01-29 |
| IL310391A (en) | 2024-03-01 |
| US20220193069A1 (en) | 2022-06-23 |
| MA52669A (fr) | 2021-02-17 |
| JP2021521111A (ja) | 2021-08-26 |
| AR114473A1 (es) | 2020-09-09 |
| WO2019195665A1 (en) | 2019-10-10 |
| EA202092410A1 (ru) | 2021-02-09 |
| JP7430643B2 (ja) | 2024-02-13 |
| IL277748B2 (en) | 2024-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250135018A1 (en) | Camptothecin peptide conjugates | |
| US20250073348A1 (en) | Camptothecin conjugates | |
| US20230381321A1 (en) | Camptothecin conjugates | |
| AU2020202853B2 (en) | PEGylated drug-linkers for improved Ligand-Drug Conjugate pharmacokinetics | |
| US20240277860A1 (en) | Camptothecin peptide conjugates | |
| AU2014369019B2 (en) | Methylene carbamate linkers for use with targeted-drug conjugates | |
| EP4321522A1 (en) | Cytotoxic compounds and conjugates thereof | |
| AU2017376926A1 (en) | Multi-drug antibody drug conjugates | |
| EA052415B1 (ru) | Конъюгаты камптотецина | |
| HK40039284A (en) | Camptothecin peptide conjugates | |
| BR122023026165A2 (pt) | Conjugados de peptídeo de camptotecina e usos dos mesmos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220922 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION Effective date: 20240726 |